摘要
目的探讨伊曲康唑对有侵袭性真菌感染病史的造血干细胞移植或化疗患者二次预防的有效性和安全性。方法将74例血液系统疾病接受化疗或造血干细胞移植患者按照入院时间分为观察组(49例)和对照组(25例),对照组给予氟康唑片,观察组给予伊曲康唑,比较两组患者的感染发生率和不良反应。结果观察组侵袭性真菌感染发生率(4.08%)均低于对照组(24.00%),差异有统计学意义(P<0.05);观察组不良反应发生率(10.20%)低于对照组(32.00%),差异有统计学意义(P<0.05)。结论对有侵袭性真菌感染病史的造血干细胞移植或化疗患者给予伊曲康唑二次预防效果显著,且不良反应发生率低,值得临床推广应用。
Objective To evaluate the efficacy and safety of itraconazole for secondary prophylaxis of previous proven or probable invasive fungal infection （IFI） in patients undergoing chemotherapy or allogeneic hematopoietic stem cell transplantation （HSCT） in agranulocytosis state. Methods A total of 74 cases with blood diseases receiving chemo- therapy or hematopoietic stem cell transplantation were divided into observation group （49 cases） and control group （25 cases） according to admission time. The control group was given Fluconazole Tablets, and the observation group were treated with itraconazole. The infection rate and adverse reaction were compared between the two groups of patients. Results The incidence of invasive fungal infection rate in the observation group （4. 08%） was lower than that of the con- trol group （24%） （P〈0. 05）. The incidence of adverse reactions in the observation group （10. 20%） was lower than that of the control group （32%） （P〈0. 05）. Conclusion Hraconazole appears to be safe and effective for secondary prophy- laxis of systemic fungal infection after chemotherapy and allogeneic HSCT and has a low incidence of adverse reactions, which is worthy of clinical application.
出处
《华南国防医学杂志》
CAS
2014年第5期458-459,476,共3页
Military Medical Journal of South China
关键词
侵袭性真菌感染
造血干细胞移植
化疗
伊曲康唑
二次预防
Invasive fungal infection
Hematopoietic stem cell transplantation
Chemotherapy
Itraconazole
Second-ary anti-fungi prophylaxis
